Immunotherapy Archives

Oncotarget News

Anti-Correlation Between KLRG1 and PD-1 in Tumor CD8 T Cells

January 21, 2025

The anti-correlation of PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells suggests the potential for combination therapy supra-additive benefits of anti-PD-1 and anti-KLRG1 therapies.”BUFFALO, NY - January... read more

Oncotarget

Mesenchymal Stem Cells in Cancer Immunotherapy: Promises and Challenges

December 3, 2024

MSCs hold great promise as a therapeutic tool in cancer immunotherapy due to their immunomodulatory properties, tumor-homing abilities, and potential as carriers for delivering therapeutic agents.”BUFFALO, NY - December 3,... read more

Oncotarget

Immunotherapy Success in KRAS G12C Adenosquamous Pancreatic Cancer

November 4, 2024

Here, we present a case of metastatic ASCP with a KRAS G12C mutation refractory to multiple lines of systemic therapy, including platinum-based chemotherapy and targeted inhibition of KRAS G12C.”BUFFALO,... read more

Oncotarget

The Role of Artificial Intelligence in Advancing Intratumoral Immunotherapy

September 19, 2024

We explore how integrating these technologies could revolutionize personalized oncology.”BUFFALO, NY- September 19, 2024 – A new editorial was published in Oncotarget's Volume 15 on September 17, 2024, entitled, “The... read more

Oncotarget

Disrupting NKG2A:HLA-E Interactions for Enhanced Anti-Cancer Immunity

August 21, 2024

there is strong preclinical evidence that disruption of NKG2A interactions with HLA-E can stimulate both NK cell and cytotoxic T cell effector functions against cancer.”BUFFALO, NY- August 21, 2024 –... read more

Oncotarget

Starving Cancer Cells to Enhance DNA Damage and Immunotherapy Response

June 26, 2024

Depleting amino acid[s] likely expose[s] the Achilles heel of the cancer and exacerbate[s] DNA repair-targeted and immune-based therapy response.”BUFFALO, NY- June 26, 2024 – A new research... read more

Oncotarget

Targeting GITR in cancer immunotherapy – there is no perfect knowledge

June 21, 2023

the experience with GITR targeting in patients may inform the development of either novel or next-generation immunotherapy approaches.”BUFFALO, NY- June 21, 2023 – A new research perspective was published in... read more

Figure 1: Response to docetaxel in second or third line treatment for non-small cell lung cancer after a treatment with chemo-immunotherapy.

Oncotarget

Value of Chemotherapy Post Immunotherapy in Stage IV Non-Small Cell Lung Cancer

June 7, 2023

large multicenter prospective randomized trials are needed to provide the clinical evidence for the use of [chemotherapy] in second line and third-line post [immunotherapy] failure.”BUFFALO, NY- June 7, 2023 –... read more

Figure 1: Demographic factors, comorbidities and therapy regime of the melanoma patients in percentage, age in years.

Oncotarget

Oncotarget | Impact of Covid-19 on Management of Patients With Metastatic Melanoma

January 11, 2023

In this study, we aimed to analyze our experience with patients suffering from Sars-CoV-2 infection while receiving treatment for metastatic melanoma.” BUFFALO, NY- January 11, 2023 – A new research... read more

Figure 4: Wnt pathway expression in tumors from NeuT/ATTAC mice.

Oncotarget

Oncotarget | Resistance of MMTV-NeuT/ATTAC Mice to Anti-PD-1 Immune Checkpoint Therapy is Associated With Macrophage Infiltration and Wnt Pathway Expression

January 5, 2023

One of the impediments to successful cancer therapy is the heterogeneity and cellular plasticity of the tumor and TME [22, 23].” BUFFALO, NY- January 5, 2023 – A new research... read more